Home
Stock Market News
Market Sentiment
Trending Industries
Blogs
Contact us
Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.
Ascendis Pharma receives 7 years of orphan drug exclusivity from the FDA for Yorvipath, a treatment for hypoparathyroidism.